AH6809 antagonizes non-small cell lung cancer prostaglandin receptors
- 30 April 2002
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 36 (1) , 33-42
- https://doi.org/10.1016/s0169-5002(01)00476-7
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cellsLung Cancer, 2001
- Lipoxygenase Inhibitors Prevent Lung Carcinogenesis and Inhibit Non-Small Cell Lung Cancer GrowthExperimental Lung Research, 1998
- Peptides and growth factors in non-small cell lung cancerPeptides, 1996
- Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling.Journal of Clinical Investigation, 1996
- Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl terminiBritish Journal of Pharmacology, 1994
- Cloning and expression of three isoforms of the human EP3 prostanoid receptorFEBS Letters, 1994
- A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.Proceedings of the National Academy of Sciences, 1993
- Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.Journal of Clinical Investigation, 1988
- Bombesin-like peptides elevate cytosolic calcium in small cell lung cancer cellsBiochemical and Biophysical Research Communications, 1987
- Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancerNature, 1985